
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 6.180 | 33.330 | 27.150 |
Shares | 93.820 | 93.820 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 12.456 | 14.592 |
Price to Book | 1.573 | 2.189 |
Price to Sales | 2.038 | 1.932 |
Price to Cash Flow | 11.387 | 10.248 |
Dividend Yield | 4.025 | 2.651 |
5 Years Earnings Growth | 7.668 | 10.672 |
Name | Net % | Category Average |
---|---|---|
Communication Services | 23.220 | 14.160 |
Consumer Defensive | 16.960 | 6.125 |
Financial Services | 16.170 | 14.308 |
Consumer Cyclical | 13.850 | 21.640 |
Technology | 11.540 | 26.546 |
Healthcare | 7.270 | 5.297 |
Real Estate | 5.730 | 2.980 |
Industrials | 5.260 | 6.758 |
Number of long holdings: 66
Number of short holdings: 14
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Taiwan Semicon | TW0002330008 | 9.56 | 1,180.00 | +4.89% | |
Tencent Holdings | KYG875721634 | 9.08 | 561.00 | -1.06% | |
NetEase | US64110W1027 | 7.77 | 129.51 | -1.07% | |
Kweichow Moutai | CNE0000018R8 | 7.70 | 1,420.97 | -0.10% | |
China Merchants Bank H | CNE1000002M1 | 4.74 | 50.30 | -1.47% | |
Far East Horizon | HK0000077468 | 4.24 | 7.40 | -3.77% | |
CSPC Pharma | HK1093012172 | 4.16 | 10.26 | +5.99% | |
Alibaba ADR | US01609W1027 | 3.77 | 119.29 | -1.38% | |
Anhui Gujing Distillery | CNE000000K82 | 3.73 | 106.86 | -0.02% | |
Ping An Insurance | CNE1000003X6 | 2.98 | 54.35 | -0.46% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UBS Lux Equity Fund China Opportunp | 3.19B | 9.99 | -5.57 | 2.60 | ||
UBS Global Emerging Markets OpportS | 624.87M | 14.71 | 6.47 | 4.34 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review